Non-small-cell lung cancer with epidermal growth factor receptor L861Q-L833F compound mutation benefits from both afatinib and osimertinib: A case report

doi:10.12998/wjcc.v9.i27.8220

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 9, Issue 27

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3921)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series.

Item

Count

PDF

227

WORD

101

HTML

2307

Figures (1-3)

250

Sum=2885

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

370

Download

659

Sum=1029

Sep 26, 2021 (publication date) through Nov 5, 2024

Times Cited of This Article

Times Cited (1)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Report

World J Clin Cases. Sep 26, 2021; 9(27): 8220-8225
Published online Sep 26, 2021. doi: 10.12998/wjcc.v9.i27.8220

Full Size Figure Download Figure

Figure 3 Responses of lung and brain lesions to osimertinib + bevacizumab regimen. A: At docetaxel + bevacizumab failure, before osimertinib treatment; B: 2 mo after treatment initiation, both lung and brain lesions were stable; C: 3 mo after treatment, both lesions remained stable. RAH: Right/anterior/head; RPF: Right/posterior/feet; RP: Right/posterior; LA: Left/anterior; RHA: Right/head/anterior; LFP: Left/feet/posterior.

Citation: Zhang Y, Shen JQ, Shao L, Chen Y, Lei L, Wang JL. Non-small-cell lung cancer with epidermal growth factor receptor L861Q-L833F compound mutation benefits from both afatinib and osimertinib: A case report. World J Clin Cases 2021; 9(27): 8220-8225
URL: https://www.wjgnet.com/2307-8960/full/v9/i27/8220.htm
DOI: https://dx.doi.org/10.12998/wjcc.v9.i27.8220